{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(1)"],"submitter":["Thawornpan P"],"pubmed_abstract":["Plasmodium vivax Duffy Binding Protein region II (PvDBPII) is a leading vaccine candidate against blood-stage vivax malaria. Anti-PvDBPII antibodies potentially block parasite invasion by inhibition of erythrocyte binding. However, knowledge of PvDBPII-specific T cell responses is limited. Here, to assess the responses of PvDBPII-specific CD4<sup>+</sup>T cells in natural P. vivax infection, three cross-sectional studies were conducted in recovered subjects. In silico analysis was used for potential T cell epitope prediction and selection. PBMCs from P. vivax subjects were stimulated with selected peptides and examined for cytokine production by ELISPOT or intracellular cytokine staining. Six dominant T cell epitopes were identified. Peptide-driven T cell responses showed effector memory CD4<sup>+</sup>T cell phenotype, secreting both IFN-γ and TNF-α cytokines. Single amino acid substitutions in three T cell epitopes altered levels of IFN-γ memory T cell responses. Seropositivity of anti-PvDBPII antibodies were detected during acute malaria (62%) and persisted up to 12 months (11%) following P. vivax infection. Further correlation analysis showed four out of eighteen subjects had positive antibody and CD4<sup>+</sup>T cell responses to PvDBPII. Altogether, PvDBPII-specific CD4<sup>+</sup>T cells were developed in natural P. vivax infections. Data on their antigenicity could facilitate development of an efficacious vivax malaria vaccine."],"journal":["Scientific reports"],"pagination":["7741"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10177721"],"repository":["biostudies-literature"],"pubmed_title":["Characterization of Duffy Binding Protein II-specific CD4<sup>+</sup>T cell responses in Plasmodium vivax patients."],"pmcid":["PMC10177721"],"pubmed_authors":["Thawornpan P","De SL","Chootong P","Leepiyasakulchai C","Wangriatisak K","Malee C","Ntumngia FB","Adams JH","Kochayoo P"],"additional_accession":[]},"is_claimable":false,"name":"Characterization of Duffy Binding Protein II-specific CD4<sup>+</sup>T cell responses in Plasmodium vivax patients.","description":"Plasmodium vivax Duffy Binding Protein region II (PvDBPII) is a leading vaccine candidate against blood-stage vivax malaria. Anti-PvDBPII antibodies potentially block parasite invasion by inhibition of erythrocyte binding. However, knowledge of PvDBPII-specific T cell responses is limited. Here, to assess the responses of PvDBPII-specific CD4<sup>+</sup>T cells in natural P. vivax infection, three cross-sectional studies were conducted in recovered subjects. In silico analysis was used for potential T cell epitope prediction and selection. PBMCs from P. vivax subjects were stimulated with selected peptides and examined for cytokine production by ELISPOT or intracellular cytokine staining. Six dominant T cell epitopes were identified. Peptide-driven T cell responses showed effector memory CD4<sup>+</sup>T cell phenotype, secreting both IFN-γ and TNF-α cytokines. Single amino acid substitutions in three T cell epitopes altered levels of IFN-γ memory T cell responses. Seropositivity of anti-PvDBPII antibodies were detected during acute malaria (62%) and persisted up to 12 months (11%) following P. vivax infection. Further correlation analysis showed four out of eighteen subjects had positive antibody and CD4<sup>+</sup>T cell responses to PvDBPII. Altogether, PvDBPII-specific CD4<sup>+</sup>T cells were developed in natural P. vivax infections. Data on their antigenicity could facilitate development of an efficacious vivax malaria vaccine.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2024-11-12T10:29:39.404Z","creation":"2024-11-12T10:29:39.404Z"},"accession":"S-EPMC10177721","cross_references":{"pubmed":["37173361"],"doi":["10.1038/s41598-023-34903-4"]}}